Invention Grant
- Patent Title: FcRn-specific human antibody and composition for treatment of autoimmune diseases
-
Application No.: US14899554Application Date: 2014-06-20
-
Publication No.: US10280207B2Publication Date: 2019-05-07
- Inventor: Sung Wuk Kim , Seung Kook Park , Jae Kap Jeong , Min Sun Kim , Eun Sun Kim , Jeong Haing Heo , Yeon Jung Song , Hae-Young Yong , Dongok Shin
- Applicant: Hanall Biopharma Co., Ltd.
- Applicant Address: KR Daejeon
- Assignee: HANALL BIOPHARMA CO., LTD.
- Current Assignee: HANALL BIOPHARMA CO., LTD.
- Current Assignee Address: KR Daejeon
- Agency: Hultquist, PLLC
- Agent Steven J. Hultquist
- Priority: KR10-2013-0071185 20130620
- International Application: PCT/KR2014/005495 WO 20140620
- International Announcement: WO2014/204280 WO 20141224
- Main IPC: C07K16/00
- IPC: C07K16/00 ; C12P21/08 ; A61K39/395 ; A61K39/40 ; A61K49/00 ; C07K16/28 ; G01N33/566 ; C07K14/705
Abstract:
The present invention relates to a human antibody specific for FcRn that is a receptor with a high affinity for IgG, a production method thereof, a composition for treating autoimmune disease, which comprises the antibody, and a method of treating and diagnosing autoimmune disease using the same. The FcRn-specific antibody according to the present invention can bind to FcRn non-competitively with IgG or the like to reduce serum auto-antibody levels, and thus can be used for the treatment of autoimmune diseases.
Public/Granted literature
- US20160137713A1 FCRN-SPECIFIC HUMAN ANTIBODY AND COMPOSITION FOR TREATMENT OF AUTOIMMUNE DISEASES Public/Granted day:2016-05-19
Information query
